Katy Beckermann, MD, PhD, of Vanderbilt-Ingram Cancer Center, and Michael Atkins, MD, of Georgetown Lombardi Comprehensive Cancer Center, consider the potential of LAG-3 as a checkpoint inhibitor in kidney cancer treatment, highlighting biomarkers for patient selection and the importance of frontline therapy in increasing cure rates.

In the fourth segment of the roundtable series, the panel swapped opinions on data pertaining to CheckMate 914, CheckMate 214, and IMDC selection criteria.

In the fifth segment of the roundtable series, the panel highlighted the CheckMate 9ER study and implications for clinical practice.

In the sixth segment of the roundtable series, the panel transitioned to relevant considerations from the CheckMate 67T study and shared their thoughts on the potential of subcutaneous nivolumab administration.

In the final segment of the roundtable series, the panel forecasted some of the major questions that will likely be answered in the coming years regarding belzutifan, triplet combinations, and more.

Latest news from GU Oncology Now on advanced renal cell carcinoma. 

Stay up-to-date with the latest research and clinical updates on renal cell carcinoma from the 2024 ASCO GU Symposium.